IL176830A0 - Nk-1 receptor antagonists to improve anesthesia recovery - Google Patents

Nk-1 receptor antagonists to improve anesthesia recovery

Info

Publication number
IL176830A0
IL176830A0 IL176830A IL17683006A IL176830A0 IL 176830 A0 IL176830 A0 IL 176830A0 IL 176830 A IL176830 A IL 176830A IL 17683006 A IL17683006 A IL 17683006A IL 176830 A0 IL176830 A0 IL 176830A0
Authority
IL
Israel
Prior art keywords
receptor antagonists
anesthesia recovery
improve anesthesia
improve
recovery
Prior art date
Application number
IL176830A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL176830A0 publication Critical patent/IL176830A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL176830A 2004-01-30 2006-07-13 Nk-1 receptor antagonists to improve anesthesia recovery IL176830A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54069704P 2004-01-30 2004-01-30
PCT/IB2005/000010 WO2005082366A1 (en) 2004-01-30 2005-01-06 Nk-1 receptor antagonists anesthesia recovery

Publications (1)

Publication Number Publication Date
IL176830A0 true IL176830A0 (en) 2006-10-31

Family

ID=34910695

Family Applications (1)

Application Number Title Priority Date Filing Date
IL176830A IL176830A0 (en) 2004-01-30 2006-07-13 Nk-1 receptor antagonists to improve anesthesia recovery

Country Status (14)

Country Link
US (1) US20070155782A1 (enExample)
EP (1) EP1713479A1 (enExample)
JP (1) JP2007519701A (enExample)
KR (1) KR100880391B1 (enExample)
CN (1) CN1913893A (enExample)
AU (1) AU2005216706B2 (enExample)
BR (1) BRPI0507325A (enExample)
CA (1) CA2554823A1 (enExample)
IL (1) IL176830A0 (enExample)
MX (1) MXPA06007964A (enExample)
NO (1) NO20062965L (enExample)
RU (1) RU2337685C2 (enExample)
WO (1) WO2005082366A1 (enExample)
ZA (1) ZA200605149B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1713504T1 (sl) 2004-01-30 2017-10-30 Zoetis Services Llc Protimikrobni konzervansi za dosego večodmerne formulacije z uporabo beta-ciklodekstrinov za tekoče odmerne oblike
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
RU2489765C1 (ru) * 2012-01-10 2013-08-10 Открытое акционерное общество "Научно-исследовательский институт газоразрядных приборов "Плазма" (ОАО "Плазма") Способ изготовления газонаполненного разрядника
CN114984223B (zh) * 2022-05-31 2023-06-20 中国人民解放军陆军军医大学第二附属医院 生长激素促分泌素受体拮抗剂在制备吸入麻醉复苏制剂中的应用
AT527172A1 (de) * 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US540897A (en) 1895-06-11 Harold f
US540644A (en) 1895-06-11 del yalle
SK278788B6 (sk) 1991-05-31 1998-02-04 Pfizer Inc. Chinuklidínové deriváty, spôsob ich prípravy a pou
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
WO2003009848A1 (en) * 2001-07-20 2003-02-06 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses

Also Published As

Publication number Publication date
ZA200605149B (en) 2007-11-28
MXPA06007964A (es) 2007-01-26
WO2005082366A1 (en) 2005-09-09
US20070155782A1 (en) 2007-07-05
KR20060127934A (ko) 2006-12-13
WO2005082366A8 (en) 2005-12-15
RU2006126828A (ru) 2008-03-10
NO20062965L (no) 2006-07-21
RU2337685C2 (ru) 2008-11-10
CN1913893A (zh) 2007-02-14
AU2005216706A1 (en) 2005-09-09
AU2005216706B2 (en) 2007-11-29
CA2554823A1 (en) 2005-09-09
BRPI0507325A (pt) 2007-07-03
JP2007519701A (ja) 2007-07-19
KR100880391B1 (ko) 2009-01-30
EP1713479A1 (en) 2006-10-25

Similar Documents

Publication Publication Date Title
TWI372751B (en) Pyrimidines as prostaglandin d2 receptor antagonists
IL189866A0 (en) Histamine-3 receptor antagonists
ZA200606314B (en) Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
IL182355A0 (en) Thrombin receptor antagonists
IL183538A0 (en) Substituted piperazines as cb1 antagonists
ZA200705449B (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
ZA200801035B (en) Substituted piperazines as metabotropic glutamate receptor antagonists
IL190686A0 (en) Il-21 receptor antagonists
IL237513A0 (en) Piperazindiones as oxytocin receptor antagonists
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
SI1951661T1 (sl) Antagonisti glukagonskega receptorja priprava interapevtske uporabe
SI1951658T1 (sl) Antagonisti glukagonskega receptorja priprava interapevtska uporaba
TWI341198B (en) Hydroisoindoline tachykinin receptor antagonists
EP1812008A4 (en) ANTAGONISTS OF THE IL-8 RECEPTOR
ZA200801033B (en) Acetylenic piperazines as metabotropic glutamate receptor antagonists
IL178622A0 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
ZA200801034B (en) Bicyclic piperazines as metabotropic glutamate receptor antagonists
IL176830A0 (en) Nk-1 receptor antagonists to improve anesthesia recovery
IL185640A0 (en) Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
ZA200609846B (en) Mercaptoimidazoles as CCR2 receptor antagonists
ZA200605574B (en) Hydroisoindoline tachykinin receptor antagonists
SI1711465T1 (sl) Antagonisti hidroizoindolin tahikininskega receptorja
PL1951659T3 (pl) Antagoniści receptora glukagonu, wytwarzanie i zastosowania terapeutyczne